Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Inmune Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
06/24/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation"
06/17/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Feature in NetworkNewsWire Broadcast June 11, 2019"
06/10/2019 SC 13G/A Toucan Capital Fund III, L.P. reports a 11.1% stake in INMUNE BIO INC.
06/06/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference on June 4, 2019"
06/05/2019 4 Powers Linda F (10% Owner) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 10,000 shares @ $6, valued at $60k
06/04/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
06/04/2019 4 Juda Scott (Director) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 10,000 shares @ $6, valued at $60k
06/04/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 10,000 shares @ $6, valued at $60k
06/04/2019 4 Tesi Raymond Joseph (President & CEO) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 10,000 shares @ $6, valued at $60k
05/29/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th"
05/24/2019 8-K/A Quarterly results
05/24/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sublease between INmune Bio Inc. and CTI-Clinical Trial Services, Inc"
05/20/2019 4/A Tesi Raymond Joseph (President & CEO) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 11,100 shares @ $10.75, valued at $119.3k
05/20/2019 4/A Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 5,000 shares @ $10.71, valued at $53.6k
05/17/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi",
"Amendment to Securities Purchase Agreement between INmune Bio, Inc. and David J. Moss"
05/16/2019 8-K Quarterly results
Docs: "Purchase Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC",
"INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire",
"INmune Bio, Inc."
05/15/2019 10-Q Quarterly Report for the period ended March 31, 2019
05/13/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "EX - 99.1"
05/10/2019 4 Powers Linda F (10% Owner) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 61,667 shares @ $9, valued at $555k
05/10/2019 3 Powers Linda F (10% Owner) has filed a Form 3 on Inmune Bio, Inc.
05/09/2019 4/A Tesi Raymond Joseph (President & CEO) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 11,100 shares @ $9, valued at $99.9k
05/07/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 5,000 shares @ $9, valued at $45k
05/06/2019 4 Tesi Raymond Joseph (Chairman) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 11,100 shares @ $9.9, valued at $109.9k
05/06/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
04/29/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Waiver from Pacific Seaboard Investments Ltd"
04/19/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit LA JOLLA, Calif., April 17, 2019 -- INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the Neuroimmunology Drug Development Summit in Boston on April 17. The poster will address the Phase 1b trial on the company’s drug candidate XPro1595 for patients with mild to moderate Alzheimer’s disease. ”Because of our focus on neuroinflammation as a cause of neurologic disease, we have designed a Phase 1 trial that measures traditional and novel biomarkers of inflammation as a first step in our Alzheimer’s d..."
04/12/2019 8-K Quarterly results
04/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "NASDAQ Closing Bell Release"
03/29/2019 10-K Annual Report for the period ended December 31, 2018
03/13/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Website Release"
03/04/2019 SC 13G Toucan Capital Fund III, L.P. reports a 7.2% stake in IMMUNE BIO INC.
02/13/2019 8-K Quarterly results
02/11/2019 SC 13D Lowdell Mark William reports a 17.6% stake in IMMUNE BIO INC.
02/11/2019 SC 13D Tesi Raymond Joseph reports a 18.1% stake in IMMUNE BIO INC.
  Next >>

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy